Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing.
How Endpoints News will cover the future of the healthcare industry
I’m Lydia Ramsey Pflanzer, and for eight years, I’ve covered every part of the healthcare industry, diving deep into the changing way care is paid